1887
Systematic Review Open Access
Like 0

Abstract

Background

Vaccines play a crucial role in the response to COVID-19 and their efficacy is thus of great importance.

Aim

To assess the robustness of COVID-19 vaccine efficacy (VE) trial results using the fragility index (FI) and fragility quotient (FQ) methodology.

Methods

We conducted a Cochrane and PRISMA-compliant systematic review and meta-analysis of COVID-19 VE trials published worldwide until 22 January 2023. We calculated the FI and FQ for all included studies and assessed their associations with selected trial characteristics using Wilcoxon rank sum tests and Kruskal–Wallis H tests. Spearman correlation coefficients and scatter plots were used to quantify the strength of correlation of FIs and FQs with trial characteristics.

Results

Of 6,032 screened records, we included 40 trials with 54 primary outcomes, comprising 909,404 participants with a median sample size per outcome of 13,993 (interquartile range (IQR): 8,534–25,519). The median FI and FQ was 62 (IQR: 22–123) and 0.50% (IQR: 0.24–0.92), respectively. FIs were positively associated with sample size (p < 0.001), and FQs were positively associated with type of blinding (p = 0.023). The Spearman correlation coefficient for FI with sample size was moderately strong (0.607), and weakly positive for FI and FQ with VE (0.138 and 0.161, respectively).

Conclusions

This was the largest study on trial robustness to date. Robustness of COVID-19 VE trials increased with sample size and varied considerably across several other important trial characteristics. The FI and FQ are valuable complementary parameters for the interpretation of trial results and should be reported alongside established trial outcome measures.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2023.28.22.2200706
2023-06-01
2024-07-18
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2023.28.22.2200706
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/28/22/eurosurv-28-22-4.html?itemId=/content/10.2807/1560-7917.ES.2023.28.22.2200706&mimeType=html&fmt=ahah

References

  1. Au WY, Cheung PP-H. Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. BMJ. 2022;377:e069989.  https://doi.org/10.1136/bmj-2022-069989  PMID: 35640925 
  2. Rotshild V, Hirsh-Raccah B, Miskin I, Muszkat M, Matok I. Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Sci Rep. 2021;11(1):22777.  https://doi.org/10.1038/s41598-021-02321-z  PMID: 34815503 
  3. Xing K, Tu XY, Liu M, Liang ZW, Chen JN, Li JJ, et al. Efficacy and safety of COVID-19 vaccines: a systematic review. Zhongguo Dang Dai Er Ke Za Zhi. 2021;23(3):221-8.  https://doi.org/10.7499/j.issn.1008-8830.2101133  PMID: 33691913 
  4. Ghazy RM, Ashmawy R, Hamdy NA, Elhadi YAM, Reyad OA, Elmalawany D, et al. Efficacy and Effectiveness of SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis. Vaccines (Basel). 2022;10(3):350.  https://doi.org/10.3390/vaccines10030350  PMID: 35334982 
  5. Armitage P. The design and analysis of clinical trials. Handbook of Statistics. 1996;13(7049):1-29.  https://doi.org/10.1016/S0169-7161(96)13003-0 
  6. Pollock AV, Evans M. Design and interpretation of clinical trials. Br Med J (Clin Res Ed). 1985;290(6463):243.  https://doi.org/10.1136/bmj.290.6463.243  PMID: 3917772 
  7. Greenland S, Senn SJ, Rothman KJ, Carlin JB, Poole C, Goodman SN, et al. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. Eur J Epidemiol. 2016;31(4):337-50.  https://doi.org/10.1007/s10654-016-0149-3  PMID: 27209009 
  8. Sterne JA, Davey Smith G. Sifting the evidence-what’s wrong with significance tests? BMJ. 2001;322(7280):226-31.  https://doi.org/10.1136/bmj.322.7280.226  PMID: 11159626 
  9. Wasserstein RL, Lazar NA. The ASA Statement on p-Values: Context, Process, and Purpose. Am Stat. 2016;70(2):129-33.  https://doi.org/10.1080/00031305.2016.1154108 
  10. Pocock SJ. Current issues in the design and interpretation of clinical trials. Br Med J (Clin Res Ed). 1985;290(6461):39-42.  https://doi.org/10.1136/bmj.290.6461.39  PMID: 3917328 
  11. Feinstein AR. The unit fragility index: an additional appraisal of "statistical significance" for a contrast of two proportions. J Clin Epidemiol. 1990;43(2):201-9.  https://doi.org/10.1016/0895-4356(90)90186-S  PMID: 2303850 
  12. Walter SD. Statistical significance and fragility criteria for assessing a difference of two proportions. J Clin Epidemiol. 1991;44(12):1373-8.  https://doi.org/10.1016/0895-4356(91)90098-T  PMID: 1753268 
  13. Walsh M, Srinathan SK, McAuley DF, Mrkobrada M, Levine O, Ribic C, et al. The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index. J Clin Epidemiol. 2014;67(6):622-8.  https://doi.org/10.1016/j.jclinepi.2013.10.019  PMID: 24508144 
  14. Andrade C. The Use and Limitations of the Fragility Index in the Interpretation of Clinical Trial Findings. J Clin Psychiatry. 2020;81(2):20f13334.  https://doi.org/10.4088/JCP.20f13334  PMID: 32237291 
  15. Khan MS, Fonarow GC, Friede T, Lateef N, Khan SU, Anker SD, et al. Application of the Reverse Fragility Index to Statistically Nonsignificant Randomized Clinical Trial Results. JAMA Netw Open. 2020;3(8):e2012469.  https://doi.org/10.1001/jamanetworkopen.2020.12469  PMID: 32756927 
  16. Murad MH, Kara Balla A, Khan MS, Shaikh A, Saadi S, Wang Z. Thresholds for interpreting the fragility index derived from sample of randomised controlled trials in cardiology: a meta-epidemiologic study. BMJ Evid Based Med. 2023;28(2):133-6.  https://doi.org/10.1136/bmjebm-2021-111858  PMID: 35264405 
  17. Ahmed W, Fowler RA, McCredie VA. Does Sample Size Matter When Interpreting the Fragility Index? Crit Care Med. 2016;44(11):e1142-3.  https://doi.org/10.1097/CCM.0000000000001976  PMID: 27755081 
  18. Huang X, Chen B, Thabane L, Adachi JD, Li G. Fragility of results from randomized controlled trials supporting the guidelines for the treatment of osteoporosis: a retrospective analysis. Osteoporos Int. 2021;32(9):1713-23.  https://doi.org/10.1007/s00198-021-05865-y  PMID: 33595680 
  19. Chase Kruse B, Matt Vassar B. Unbreakable? An analysis of the fragility of randomized trials that support diabetes treatment guidelines. Diabetes Res Clin Pract. 2017;134:91-105.  https://doi.org/10.1016/j.diabres.2017.10.007  PMID: 29037877 
  20. Goerke K, Parke M, Horn J, Meyer C, Dormire K, White B, et al. Are results from randomized trials in anesthesiology robust or fragile? An analysis using the fragility index. Int J Evid-Based Healthc. 2020;18(1):116-24.  https://doi.org/10.1097/XEB.0000000000000200  PMID: 31415254 
  21. Shalhout SZ, Bloom R, Drake L, Miller DM. Evaluation of the fragility of pivotal trials used to support US Food and Drug Administration approval for plaque psoriasis. J Am Acad Dermatol. 2021;84(2):354-60.  https://doi.org/10.1016/j.jaad.2020.04.057  PMID: 32320767 
  22. Rickard M, Lorenzo AJ, Hannick JH, Blais A-S, Koyle MA, Bägli DJ. Over-reliance on P Values in Urology: Fragility of Findings in the Hydronephrosis Literature Calls for Systematic Reporting of Robustness Indicators. Urology. 2019;133:204-10.  https://doi.org/10.1016/j.urology.2019.03.045  PMID: 31374290 
  23. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane; 2022. Available from www.training.cochrane.org/handbook
  24. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160.  https://doi.org/10.1136/bmj.n160  PMID: 33781993 
  25. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372(71):n71.  https://doi.org/10.1136/bmj.n71  PMID: 33782057 
  26. “Covidence - Better systematic review management.” [Accessed: 30-Dec-2021]. Available from: https://www.covidence.org/
  27. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. , Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.  https://doi.org/10.1136/bmj.d5928  PMID: 22008217 
  28. ClinCalc. “Fragility Index Calculator.” [Accessed: 21 Feb 2023]. Available: https://clincalc.com/Stats/FragilityIndex.aspx
  29. Schröder A, Muensterer OJ, Oetzmann von Sochaczewski C. Meta-analyses in paediatric surgery are often fragile: implications and consequences. Pediatr Surg Int. 2021;37(3):363-7.  https://doi.org/10.1007/s00383-020-04827-5  PMID: 33454848 
  30. T. S. L. College Station. “Stata Statistical Software: Release 16.” StataCorp, 2019.
  31. Docherty KF, Campbell RT, Jhund PS, Petrie MC, McMurray JJV. How robust are clinical trials in heart failure? Eur Heart J. 2017;38(5):338-45.  https://doi.org/10.1093/eurheartj/ehw427  PMID: 27742808 
  32. Khan MS, Ochani RK, Shaikh A, Usman MS, Yamani N, Khan SU, et al. Fragility Index in Cardiovascular Randomized Controlled Trials. Circ Cardiovasc Qual Outcomes. 2019;12(12):e005755.  https://doi.org/10.1161/CIRCOUTCOMES.119.005755  PMID: 31822121 
  33. Biau DJ, Kernéis S, Porcher R. Statistics in brief: the importance of sample size in the planning and interpretation of medical research. Clin Orthop Relat Res. 2008;466(9):2282-8.  https://doi.org/10.1007/s11999-008-0346-9  PMID: 18566874 
  34. Parisien RL, Constant M, Saltzman BM, Popkin CA, Ahmad CS, Li X, et al. The Fragility of Statistical Significance in Cartilage Restoration of the Knee: A Systematic Review of Randomized Controlled Trials. Cartilage. 2021;13(1_suppl):147S-55S.  https://doi.org/10.1177/19476035211012458  PMID: 33969744 
  35. Parisien RL, Ehlers C, Cusano A, Tornetta P 3rd, Li X, Wang D. The Statistical Fragility of Platelet-Rich Plasma in Rotator Cuff Surgery: A Systematic Review and Meta-analysis. Am J Sports Med. 2021;49(12):3437-42.  https://doi.org/10.1177/0363546521989976  PMID: 33646884 
  36. Maldonado DR, Go CC, Huang BH, Domb BG. The Fragility Index of Hip Arthroscopy Randomized Controlled Trials: A Systematic Survey. Arthroscopy. 2021;37(6):1983-9.  https://doi.org/10.1016/j.arthro.2021.01.049  PMID: 33539980 
  37. Tignanelli CJ, Napolitano LM. The Fragility Index in Randomized Clinical Trials as a Means of Optimizing Patient Care. JAMA Surg. 2019;154(1):74-9.  https://doi.org/10.1001/jamasurg.2018.4318  PMID: 30422256 
  38. Vargas M, Marra A, Buonanno P, Coviello A, Iacovazzo C, Servillo G. Fragility Index and Fragility Quotient in Randomized Controlled Trials on Corticosteroids in ARDS Due to COVID-19 and Non-COVID-19 Etiology. J Clin Med. 2021;10(22):5287.  https://doi.org/10.3390/jcm10225287  PMID: 34830569 
  39. Itaya T, Isobe Y, Suzuki S, Koike K, Nishigaki M, Yamamoto Y. The Fragility of Statistically Significant Results in Randomized Clinical Trials for COVID-19. JAMA Netw Open. 2022;5(3):e222973.  https://doi.org/10.1001/jamanetworkopen.2022.2973  PMID: 35302631 
  40. Carter RE, McKie PM, Storlie CB. The Fragility Index: a P-value in sheep’s clothing? Eur Heart J. 2017;38(5):346-8.  https://doi.org/10.1093/eurheartj/ehw495  PMID: 28417139 
  41. Niforatos JD, Zheutlin AR, Chaitoff A, Pescatore RM. The fragility index of practice changing clinical trials is low and highly correlated with P-values. J Clin Epidemiol. 2020;119:140-2.  https://doi.org/10.1016/j.jclinepi.2019.09.029  PMID: 31711911 
  42. Chaitoff A, Zheutlin A, Niforatos JD. The Fragility Index and Trial Significance. JAMA Intern Med. 2020;180(11):1554.  https://doi.org/10.1001/jamainternmed.2020.4787  PMID: 32955584 
  43. Acuna SA, Sue-Chue-Lam C, Dossa F. The Fragility Index-P Values Reimagined, Flaws and All. JAMA Surg. 2019;154(7):674.  https://doi.org/10.1001/jamasurg.2019.0567  PMID: 30994897 
  44. Baer BR, Gaudino M, Charlson M, Fremes SE, Wells MT. Fragility indices for only sufficiently likely modifications. Proc Natl Acad Sci USA. 2021;118(49):e2105254118.  https://doi.org/10.1073/pnas.2105254118  PMID: 34848537 
  45. Lin L. Factors that impact fragility index and their visualizations. J Eval Clin Pract. 2021;27(2):356-64.  https://doi.org/10.1111/jep.13428  PMID: 32524768 
  46. Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021;384(22):2124-30.  https://doi.org/10.1056/NEJMoa2104882  PMID: 33835768 
  47. European Medicines Agency (EMA). “COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets,”. Amsterdam: EMA; 2021. Available from: https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots
  48. Australian Government. “ATAGI statement on AstraZeneca vaccine in response to new vaccine safety concerns,” Department of Health and Aged Care; 2021.
  49. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. , Oxford COVID Vaccine Trial Group. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881-91.  https://doi.org/10.1016/S0140-6736(21)00432-3  PMID: 33617777 
  50. Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021;326(1):35-45.  https://doi.org/10.1001/jama.2021.8565  PMID: 34037666 
  51. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. , COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-16.  https://doi.org/10.1056/NEJMoa2035389  PMID: 33378609 
  52. Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, et al. , COVID-19 Genomics UK consortium, AMPHEUS Project, Oxford COVID-19 Vaccine Trial Group. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021;397(10282):1351-62.  https://doi.org/10.1016/S0140-6736(21)00628-0  PMID: 33798499 
  53. Frenck RWJ Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. , C4591001 Clinical Trial Group. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021;385(3):239-50.  https://doi.org/10.1056/NEJMoa2107456  PMID: 34043894 
  54. Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. , 2019nCoV-302 Study Group. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl J Med. 2021;385(13):1172-83.  https://doi.org/10.1056/NEJMoa2107659  PMID: 34192426 
  55. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. , Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-81.  https://doi.org/10.1016/S0140-6736(21)00234-8  PMID: 33545094 
  56. Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. , NGS-SA Group, Wits-VIDA COVID Group. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021;384(20):1885-98.  https://doi.org/10.1056/NEJMoa2102214  PMID: 33725432 
  57. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. , C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15.  https://doi.org/10.1056/NEJMoa2034577  PMID: 33301246 
  58. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. , ENSEMBLE Study Group. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021;384(23):2187-201.  https://doi.org/10.1056/NEJMoa2101544  PMID: 33882225 
  59. Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et al. , 2019nCoV-501 Study Group. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021;384(20):1899-909.  https://doi.org/10.1056/NEJMoa2103055  PMID: 33951374 
  60. Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. , CoronaVac Study Group. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213-22.  https://doi.org/10.1016/S0140-6736(21)01429-X  PMID: 34246358 
  61. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. , Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.  https://doi.org/10.1016/S0140-6736(20)32661-1  PMID: 33306989 
  62. Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. , C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021;385(19):1761-73.  https://doi.org/10.1056/NEJMoa2110345  PMID: 34525277 
  63. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. , ENSEMBLE Study Group. Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S. N Engl J Med. 2022;386(9):847-60.  https://doi.org/10.1056/NEJMoa2117608  PMID: 35139271 
  64. Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, Aroca Martinez GJ, Bonten M, Chandler R, et al. , HERALD Study Group. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 2022;22(3):329-40.  https://doi.org/10.1016/S1473-3099(21)00677-0  PMID: 34826381 
  65. Khobragade A, Bhate S, Ramaiah V, Deshpande S, Giri K, Phophle H, et al. , ZyCoV-D phase 3 Study Investigator Group. Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. Lancet. 2022;399(10332):1313-21.  https://doi.org/10.1016/S0140-6736(22)00151-9  PMID: 35367003 
  66. Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, et al. , AstraZeneca AZD1222 Clinical Study Group. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med. 2021;385(25):2348-60.  https://doi.org/10.1056/NEJMoa2105290  PMID: 34587382 
  67. Fadlyana E, Rusmil K, Tarigan R, Rahmadi AR, Prodjosoewojo S, Sofiatin Y, et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia. Vaccine. 2021;39(44):6520-8.  https://doi.org/10.1016/j.vaccine.2021.09.052  PMID: 34620531 
  68. Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, et al. , COVAXIN Study Group. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021;398(10317):2173-84.  https://doi.org/10.1016/S0140-6736(21)02000-6  PMID: 34774196 
  69. El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. , COVE Study Group. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med. 2021;385(19):1774-85.  https://doi.org/10.1056/NEJMoa2113017  PMID: 34551225 
  70. Clemens SAC, Folegatti PM, Emary KRW, Weckx LY, Ratcliff J, Bibi S, et al. , AMPHEUS Project, Oxford COVID Vaccine Trial Team. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. Nat Commun. 2021;12(1):5861.  https://doi.org/10.1038/s41467-021-25982-w  PMID: 34615860 
  71. Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, et al. , C4591007 Clinical Trial Group. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. N Engl J Med. 2022;386(1):35-46.  https://doi.org/10.1056/NEJMoa2116298  PMID: 34752019 
  72. Thomas SJ, Perez JL, Lockhart SP, Hariharan S, Kitchin N, Bailey R, et al. Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial. Vaccine. 2022;40(10):1483-92.  https://doi.org/10.1016/j.vaccine.2021.12.046  PMID: 35131133 
  73. Pajon R, Paila YD, Girard B, Dixon G, Kacena K, Baden LR, et al. , COVE Trial Consortium. Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial. Nat Med. 2022;28(4):823-30.  https://doi.org/10.1038/s41591-022-01679-5  PMID: 35145311 
  74. Moreira EDJ Jr, Kitchin N, Xu X, Dychter SS, Lockhart S, Gurtman A, et al. , C4591031 Clinical Trial Group. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. N Engl J Med. 2022;386(20):1910-21.  https://doi.org/10.1056/NEJMoa2200674  PMID: 35320659 
  75. Halperin SA, Ye L, MacKinnon-Cameron D, Smith B, Cahn PE, Ruiz-Palacios GM, et al. , CanSino COVID-19 Global Efficacy Study Group. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet. 2022;399(10321):237-48.  https://doi.org/10.1016/S0140-6736(21)02753-7  PMID: 34953526 
  76. Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, et al. , 2019nCoV-301 Study Group. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. N Engl J Med. 2022;386(6):531-43.  https://doi.org/10.1056/NEJMoa2116185  PMID: 34910859 
  77. Bravo L, Smolenov I, Han HH, Li P, Hosain R, Rockhold F, et al. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2022;399(10323):461-72.  https://doi.org/10.1016/S0140-6736(22)00055-1  PMID: 35065705 
  78. Wang X-Y, Mahmood SF, Jin F, Cheah WK, Ahmad M, Sohail MA, et al. Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial. Emerg Microbes Infect. 2022;11(1):1910-9.  https://doi.org/10.1080/22221751.2022.2088406  PMID: 35686572 
  79. Tanriover MD, Aydin OA, Guner R, Yildiz O, Celik I, Doganay HL, et al. , On Behalf Of The Turkovac Study Group. Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial. Vaccines (Basel). 2022;10(11):1865.  https://doi.org/10.3390/vaccines10111865  PMID: 36366373 
  80. Tabarsi P, Anjidani N, Shahpari R, Mardani M, Sabzvari A, Yazdani B, et al. Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial. Clin Microbiol Infect. 2023;29(2):215-20.  https://doi.org/10.1016/j.cmi.2022.09.001  PMID: 36096430 
  81. Sobieszczyk ME, Maaske J, Falsey AR, Sproule S, Robb ML, Frenck RW Jr, et al. , AstraZeneca AZD1222 Clinical Study Group. Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months. J Clin Invest. 2022;132(18):e160565.  https://doi.org/10.1172/JCI160565  PMID: 36106642 
  82. Smolenov I, Han HH, Li P, Baccarini C, Verhoeven C, Rockhold F, et al. , SPECTRA Study Group. Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial. Lancet Infect Dis. 2022;22(7):990-1001.  https://doi.org/10.1016/S1473-3099(22)00144-X  PMID: 35447085 
  83. Marchevsky NG, Li G, Aley P, Costa Clemens SA, Barrett JR, Belij-Rammerstorfer S, et al. , Oxford COVID Vaccine Trial Group. An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females. EBioMedicine. 2022;81:104128.  https://doi.org/10.1016/j.ebiom.2022.104128  PMID: 35779491 
  84. Khairullin B, Zakarya K, Orynbayev M, Abduraimov Y, Kassenov M, Sarsenbayeva G, et al. Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up. EClinicalMedicine. 2022;50:101526.  https://doi.org/10.1016/j.eclinm.2022.101526  PMID: 35770251 
  85. Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial. Clin Infect Dis. 2023;76(3):398-407.  https://doi.org/10.1093/cid/ciac803  PMID: 36210481 
  86. Hardt K, Vandebosch A, Sadoff J, Le Gars M, Truyers C, Lowson D, et al. , ENSEMBLE2 study group. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2022;22(12):1703-15.  https://doi.org/10.1016/S1473-3099(22)00506-0  PMID: 36113538 
  87. Hager KJ, Pérez Marc G, Gobeil P, Diaz RS, Heizer G, Llapur C, et al. , CoVLP Study Team. Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine. N Engl J Med. 2022;386(22):2084-96.  https://doi.org/10.1056/NEJMoa2201300  PMID: 35507508 
  88. Dai L, Gao L, Tao L, Hadinegoro SR, Erkin M, Ying Z, et al. , ZF2001 Global Trial Group. Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults. N Engl J Med. 2022;386(22):2097-111.  https://doi.org/10.1056/NEJMoa2202261  PMID: 35507481 
/content/10.2807/1560-7917.ES.2023.28.22.2200706
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error